Skip to main content
Contact Us
Subscribe
E-Edition
38°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.24
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Arcutis to Report Third Quarter 2023 Financial Results
October 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Nasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook
October 20, 2023
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Friday. The Dow traded down 0.61% to 33,209.97 while the NASDAQ fell 1.24% to 13,022.16. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results
October 20, 2023
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.31% to 33,309.28 while the NASDAQ fell 1.09% to 13,042.83. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 20, 2023
Via
Benzinga
Analyst Expectations for Arcutis Biotherapeutics's Future
October 13, 2023
Via
Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
September 25, 2023
Via
Benzinga
Why Shares of Arcutis Biotherapeutics Fell This Week
September 07, 2023
The company released phase 3 trial results for an atopic dermatitis cream.
Via
The Motley Fool
Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
October 20, 2023
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday.
Via
Benzinga
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
October 20, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
October 20, 2023
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
October 20, 2023
We're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching on Friday morning!
Via
InvestorPlace
Arcutis Announces Pricing of $100 Million Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 19, 2023
Via
Benzinga
Arcutis Announces Proposed Public Offering
October 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
October 13, 2023
Via
Benzinga
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
October 13, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
October 06, 2023
Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
September 27, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
September 26, 2023
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
September 25, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis
September 19, 2023
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its...
Via
Benzinga
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
September 19, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
September 12, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
US Stocks Mostly Higher; RH Posts Upbeat Earnings
September 08, 2023
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
September 07, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present at Upcoming Investor Conference
September 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks Due for a Massive Short Squeeze
August 31, 2023
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters.
Via
InvestorPlace
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
August 31, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
August 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 21, 2023
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
